Tags

Type your tag names separated by a space and hit enter

Chagas disease.
Lancet. 2010 Apr 17; 375(9723):1388-402.Lct

Abstract

Chagas disease is a chronic, systemic, parasitic infection caused by the protozoan Trypanosoma cruzi, and was discovered in 1909. The disease affects about 8 million people in Latin America, of whom 30-40% either have or will develop cardiomyopathy, digestive megasyndromes, or both. In the past three decades, the control and management of Chagas disease has undergone several improvements. Large-scale vector control programmes and screening of blood donors have reduced disease incidence and prevalence. Although more effective trypanocidal drugs are needed, treatment with benznidazole (or nifurtimox) is reasonably safe and effective, and is now recommended for a widened range of patients. Improved models for risk stratification are available, and certain guided treatments could halt or reverse disease progression. By contrast, some challenges remain: Chagas disease is becoming an emerging health problem in non-endemic areas because of growing population movements; early detection and treatment of asymptomatic individuals are underused; and the potential benefits of novel therapies (eg, implantable cardioverter defibrillators) need assessment in prospective randomised trials.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Rassi A
Division of Cardiology, Anis Rassi Hospital, Goiânia, GO, Brazil. arassijr@terra.com.br
Rassi A
No affiliation info available
Marin-Neto JA
No affiliation info available

MeSH

Acute DiseaseChagas CardiomyopathyChagas DiseaseChronic DiseaseHumansTrypanosoma cruzi

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

20399979

Clinical Trial Links

Cardiac Contractility Modulation in Chagas Heart Disease
New Therapies and Biomarkers for Chagas Infection
Oral Fexinidazole Dosing Regimens for the Treatment of Adults With Chronic Indeterminate Chagas Disease

Citation

Rassi, Anis, et al. "Chagas Disease." Lancet (London, England), vol. 375, no. 9723, 2010, pp. 1388-402.
Rassi A, Rassi A, Marin-Neto JA. Chagas disease. Lancet. 2010;375(9723):1388-402.
Rassi, A., Rassi, A., & Marin-Neto, J. A. (2010). Chagas disease. Lancet (London, England), 375(9723), 1388-402. https://doi.org/10.1016/S0140-6736(10)60061-X
Rassi A, Rassi A, Marin-Neto JA. Chagas Disease. Lancet. 2010 Apr 17;375(9723):1388-402. PubMed PMID: 20399979.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Chagas disease. AU - Rassi,Anis,Jr AU - Rassi,Anis, AU - Marin-Neto,José Antonio, PY - 2010/4/20/entrez PY - 2010/4/20/pubmed PY - 2010/5/4/medline SP - 1388 EP - 402 JF - Lancet (London, England) JO - Lancet VL - 375 IS - 9723 N2 - Chagas disease is a chronic, systemic, parasitic infection caused by the protozoan Trypanosoma cruzi, and was discovered in 1909. The disease affects about 8 million people in Latin America, of whom 30-40% either have or will develop cardiomyopathy, digestive megasyndromes, or both. In the past three decades, the control and management of Chagas disease has undergone several improvements. Large-scale vector control programmes and screening of blood donors have reduced disease incidence and prevalence. Although more effective trypanocidal drugs are needed, treatment with benznidazole (or nifurtimox) is reasonably safe and effective, and is now recommended for a widened range of patients. Improved models for risk stratification are available, and certain guided treatments could halt or reverse disease progression. By contrast, some challenges remain: Chagas disease is becoming an emerging health problem in non-endemic areas because of growing population movements; early detection and treatment of asymptomatic individuals are underused; and the potential benefits of novel therapies (eg, implantable cardioverter defibrillators) need assessment in prospective randomised trials. SN - 1474-547X UR - https://www.unboundmedicine.com/medline/citation/20399979/full_citation L2 - https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(10)60061-X DB - PRIME DP - Unbound Medicine ER -